Functional evidence of des-Arg10-kallidin enzymatic inactivating pathway in isolated human umbilical vein

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 375, Issue 3, 2007, Pages 221-229

  Nowak, Wanda ^a   Goldschmidt, Ezequiel Dario ^a   Falcioni, Alejandra Georgina ^a   Pugliese, Mariana Ines ^a   Errasti, Andrea Emilse ^a   Pelorosso, Facundo German ^a   Daray, Federico Manuel ^a   Gago, Juan Ezequiel ^a   Rothlin, Rodolfo Pedro ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Aminopeptidase M; Angiotensin converting enzyme; B1 receptor; Biophase; Des Arg10 kallidin; Human umbilical vein; Neutral endopeptidase; Potentiation

Indexed keywords

AMASTATIN; AMINOPEPTIDASE; BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BRADYKININ DERIVATIVE; BRADYKININ[9 DEARGININE 8 DEXTRO PHENYLALANINE SARCOSINE]; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; KALLIDIN[1-9]; MEMBRANE METALLOENDOPEPTIDASE; PHOSPHORAMIDON; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; NORMAL HUMAN; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; VASOCONSTRICTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIGENS, CD13; BRADYKININ; CAPTOPRIL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FEMALE; GLYCOPEPTIDES; HUMANS; KALLIDIN; METALLOPROTEASES; NEPRILYSIN; PEPTIDES; PROTEASE INHIBITORS; RECEPTOR, BRADYKININ B1; UMBILICAL VEINS; VASOCONSTRICTION;

EID: 34047133246     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-007-0145-y     Document Type: Article

References (51)

1. Ahmad S, Ward PE (1990) Role of aminopeptidase activity in the regulation of the pressor activity of circulating angiotensins. J Pharmacol Exp Ther 252(2):643-650
2. Altura BM, Malaviya D, Reich CF, Orkin LR (1972) Effects of vasoactive agents on isolated human umbilical arteries and veins. Am J Physiol 222:345-355
3. 1 receptors in allergic airway inflammation. J Immunol 169: 2054-2060
4. Cruden NLM, Fox KAA, Ludlam CA, Johnston NR, Newby DE (2004) Neutral endopetidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition. Hypertension 44:913-918
5. Cyr M, Lepage Y, Blais C Jr, Gervais N, Cugno M, Rouleau JL, Adam A (2001) Bradykinin and des-Arg9-bradykinin metabolic pathways and kinetics of activation of human plasma. Am J Physiol Heart Circ Physiol 281:H275-H283
6. deBlois D, Horlick RA (2001) Endotoxin sensitization to kinin B(1) receptor agonist in a non-human primate model: haemodynamic and pro-inflammatory effects. Br J Pharmacol 132(1):327-335
7. De Lean A, Munson P J, Rodbard D (1978) Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol Gastrointest Liver Physiol 235(2):G97-G102
8. Dendorfer A, Reibmann S, Wolfrum S, Raasch W, Dominiak P (2001) Potentiation of kinin analogues by ramiprilat is exclusively related to their degradation. Hypertension 38:142-146
9. 1 receptors for kinins. J Pharmacol Exp Ther 259(3):997-1003
10. Drapeau G, Audet R, Levesque L, Godin D, Marceau F (1993) Development and in vivo evaluation of metabolically resistant antagonists of B1 receptors for kinins. J Pharmacol Exp Ther 266 (1):192-199
11. 9-bradykinin in human coronary arteries. Br J Pharmacol 116:3083-3085
12. Eisenbarth H, Rukwied R, Petersen M, Schmelz M (2004) Sensitization to bradykinin B1 and B2 receptor activation in UV-B irradiated human skin. Pain 110:197-204
13. Emanueli C, Bonaria Salis M, Stacca T, Pintus G, Kirchmair R, Isner JM, Pinna A, Gaspa L, Regoli D, Cayla C, Pesquero JB, Bader M, Madeddu P (2002) Targeting kinin B1 receptor for therapeutic neovascularization. Circulation 105(3):360-366
14. 1-adrenoceptor subtypes mediating vasoconstriction in human umbilical vein. Br J Pharmacol 126:437-442
15. Ferguson J (1939) The use of chemical potentials as indices of toxicity. Proc R Soc London 127:387-404
16. Fortin JP, Gera L, Bouthillier J, Stewart JM, Adam A, Marceau F (2005) Endogenous aminopeptidase N decreases the potency of peptide agonists and antagonists of the kinin B1 receptors in the rabbit aorta. J Pharmacol Exp Ther 314:1169-1176
17. Furchgott RF (1955) The pharmacology of vascular smooth muscle. Pharmacol Rev 7:183-265
18. Gafford JT, Skidgel RA, Erdös EG, Hersh LB (1983) Human kidney "enkephalinase", a neutral metalloendopeptidase that cleaves active peptides. Biochemistry 22(13):3265-3271
19. Gera L, Fortin JF, Adam A, Stewart JM, Marceau F (2006) Discovery of a dual-function peptide that combines aminopeptidase N inhibition and kinin B1 receptor antagonism. J Pharmacol Exp Ther 317:300-308
20. Gobeil F, Pheng LH, Badini I, Nguyen-Le XK, Pizard A, Rizzi A, Blouin D, Regoli D (1996) Receptors for kinins in the human isolated umbilical vein. Br J Pharmacol 118:289-294
21. Gobeil F, Neugebauer W, Nguyen-Le XK, Nsa Allogho S, Pheng LH, Blouin D, Whalley ET, Regoli D (1997) Pharmacological profiles of the human and rabbit B1 receptors. Can J Physiol Pharmacol 75:591-595
22. Houle S, Landry M, Audet R, Bouthillier J, Bachvarov D, Marcaeu F (2000) Effect of allelic polymorphism of the B1 and B2 receptor genes on the contractile responses of the human umbilical veins to kinins. J Pharmacol Exp Ther 294:45-51
23. Inokuchi J, Nagamatsu A (1981) Tripeptidyl carboxypeptidase activity of kininase II (angiotensin-converting enzyme). Biochim Biophys Acta 662:300-307
24. Ito M, Itakura A, Ohno Y, Nomura M, Senga T, Nagasaka T, Mizutani S (2002) Possible activation of the rennin-angiotensin system in the feto-placental unit in preeclampsia. J Clin Endocrinol Metab 87:1871-1878
25. Koehne O, Schäper C, Graf K, Kunkel G (1998) Neutral endopeptidase 24.11: its physiologic and possibly pathophysiologic role in inflammation with special effect on respiratory inflammation. Allergy 53(11):1023-1042
26. Kuga T, Egashira K, Hirokawa Y, Tagawa T, Shimokawa M, Takeshita A (1997) Bradykinin-induced vasodilation of human coronary arteries in vivo: role of nitric oxide and angiotensin-converting enzyme. J Am Coll Cardiol 30(1):108-112
27. Kyung-Soo K, Sandeep K, Simmons WH, Brown NJ (2000) Inhibition of aminopeptidase P potentiates wheal response to bradykinin in angiotensin-converting enzyme inhibitor-treated humans. J Pharmacol Exp Ther 292:295-298
28. Lagneux C, Adam A, Lamontagne D (2003) A study of the madiators involved in the protection induced by exogenous kinins in the isolated rat heart. Int Immunopharmacol 3(10-11):1511-1518
29. Leeb-Lundberg LMF, Marceau F, Müller-Esterl W, Pettibone DJ, Zuraw BL (2005) International Union of Pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 57:27-77
30. Llorens-Cortes C, Huang H, Vicart P, Gasc JM, Paulin D, Corvol P (1992) Identification and characterization of neutral endopeptidase in endothelial cells from venous or arterial origins. J Biol Chem 267(20):14012-14018
31. Löffler BM (2000) Endothelin-converting enzyme inhibitors: current status and perspectives. J Cardiovasc Pharmacol 35(Suppl 2):S79-S82
32. Marceau F, Regoli D (2004) Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discovery 3:845-852
33. Marceau F, Hess JF, Bachvarov DR (1998) The B1 receptor for kinins. Pharmacol Rev 50(3):357-386
34. Mc Lean PG, Perretti M, Ahluwalia A (2000) Kinin B1 receptors and the cardiovascular system: regulation of expression and function. Cardiovasc Res 48:194-210
35. Miyamoto A, Murata S, Nishio A (2002) Role of ACE and NEP in bradykinin-induced relaxation and contraction response of isolated porcine basilar artery. Naunyn-Schmiedeberg's Arch Pharmacol 365:365-370
36. Moreau ME, Garbacki N, Molinaro G, Brown, NJ, Marceau F, Adam A (2005) The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci 99(1):6-38
37. Neubig RR, Spedding M, Kenakin T, Christopoulos A (2003) International Union of Pharmacology committee on receptor nomenclature and drug classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev 55:597-606
38. Papapetropoulos A, Ryan JW, Antonov A, Virmani R, Kolodgie FD, Gerrity RG, Catravas JD (1996) Human aortic endothelial cell aminopeptidase N. Immunopharmacology 32(1-3):153-156
39. 9-kallidin-induced vasoconstrictor responses by metallopeptidase inhibition in isolated human umbilical artery. J Pharmacol Exp Ther 313(3):1355-1360
40. Pelorosso FG, Halperin AV, Palma AM, Nowak W, Errasti AE, Rothlin RP (2006) Neutral endopeptidase up-regulation in isolated human umbilical artery: involvement in desensitization of bradykinin-induced vasoconstrictor effects. J Pharmacol Exp Ther. DOI 10.1124/jpet.106.113381
41. Proud D, Baumgarten CR, Nacleiro RM, Ward PE (1987) Kinin metabolism in human nasal secretions during experimentally induced allergic rhinitis. J Immunol 138(2):428-434
42. Pujol-Lereis VA, Hita FJ, Gobbi MD, Verdi MG, Rodriguez MC, Rothlin RP (2006) Pharmacological characterization of muscarinic receptor subtypes mediating vasoconstriction of human umbilical vein. Br J Pharmacol 147(5):516-523
43. Rogerson FM, Chai SY, Schlawe I, Murray WK, Marley PD, Mendelsohn FA (1992) Presence of angiotensin converting enzyme in the adventitia of large blood vessels. J Hypertens 10 (7):615-620
44. Sardi SP, Perez H, Antunez P, Rothlin RP (1997) Bradykinin B1 receptors in human umbilical vein. Eur J Pharmacol 321:33-38
45. Sardi SP, Rey Ares V, Errasti AE, Rothlin RP (1998) Bradykinin B1 receptors in human umbilical vein: pharmacological evidence of up-regulation, and induction by interleukin-1 beta. Eur J Pharmacol 358:221-227
46. Sardi SP, Daray FM, Errasti AE, Pelorosso FG, Pujol Lereis VA, Rey Ares V, Rogines Velo MP, Rothlin RP (1999) Further pharmacological characterization of bradykinin B1 Receptor up-regulation in human umbilical vein. J Pharmacol Exp Ther 1999:1019-1025
47. Sardi SP, Errasti AE, Rey Ares V, Rogines Velo MP, Rothlin RP (2000) Bradykinin B1 receptor in isolated human umbilical vein: an experimental model of the in vitro up-regulation process. Acta Pharmacol Sin 21(2):105-110
48. 1 receptor sensitized responses in human umbilical vein. J Pharmacol Exp Ther 301(3):975-980
49. Skidgel R (1992) Bradykinin-degrading enzymes: structure, function, distribution and potential roles in cardiovascular pharmacology. J Cardiovasc Pharmacol 20(Suppl 9):S4-S9
50. Tom B, Dendorfer A, de Vries R, Saxena PR, Danser AHJ (2002) Bradykinin potentiation by ACE inhibitors: a matter of metabolism. Br J Pharmacol 137:276-284
51. Wang L, Sadoun E, Stephens RE, Ward PE (1994) Metabolism of substance P and neurokinin A by human vascular endothelium and smooth muscle. Peptides 15(3):497-503